MTRAC issued a new Commissioning Support review in August 2013. The review covers mirabegron.
The Mirabegron (Betmiga®) summary advises that this drug is suitable for prescribing in primary care. The committee considered the drug to have a lower place in therapy and relatively weak evidence due to limited comparative data with anti-muscarinics and limited long-term efficacy data. The committee also noted that NICE has recommended this treatment as an option for treating overactive bladder (OAB) only for people in whom anti-muscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects.
Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.